// App-Quantinova.ai

P201 : Long-term Safety And Effectiveness Of Eculizumab In Neuromyelitis Optica Spectrum Disorder

Researchers

Presenter

  • D. Wingerchuk

Principal Investigators

  • S. Pittock

  • A. Berthele

  • K. Fujihara

  • H. Kim

  • M. Levy

  • J. Palace

  • I. Nakashima

  • M. Terzi

  • N. Totolyan

  • S. Viswanathan

  • K. Wang

  • K. Allen

  • K. P. Fujita

  • M. Yountz

  • R. Armstrong

Medical Centers

  • Department of Hematology, Mayo Clinic, Scottsdale, AZ

  • Department of Oncology, Mayo Clinic, Rochester, MN

  • Department of Urology, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany

  • Department of Neurology, Tohoku University, Sendai, JAPAN

  • Department of Neurology, Research Institute and Hospital, National Cancer Center, Goyang, Korea, Republic of

  • Department of Oncology, Johns Hopkins University, Baltimore, MD

  • Nuffield Department of Clinical Neurosciences, University of Oxford, John Radcliffe Hospital Oxford United Kingdom

  • Medical Faculty, Ondokuz Mayıs University, Samsun, Turkey

  • Department of Neurology, First Pavlov State Medical University of St Petersburg, St Peterburg, Russian Federation

  • Department of Dermatology, Kuala Lumpur Hospital, Kuala Lumpur, Malaysia

  • Cheng Hsin General Hospital, Taipei, Taiwan

  • Vertex Pharmaceuticals Inc., Boston, MA

Locations

  • United States

  • Germany

  • Japan

  • Republic of South Korea

  • United Kingdom

  • Turkey

  • Russia

  • Malaysia

  • Taiwan

Companies

  • N/A

Study Components

Therapeutic Area

  • Central Nervous System (CNS)

  • Autoimmune (AI)

Disease

  • Neuromyelitis optica

Biomarkers

  • N/A

Drug/Treatment

  • Eculizumab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • III

Study Id's

  • NCT01892345

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved